WILMINGTON, DE — Cairn Therapeutics, a biotechnology firm, has announced the formation of its new management team and the election of a new Board of Directors.
W. Scott Evangelista, who previously served as Executive Chairman at Cairn, is now taking the helm as CEO and Chief Financial Officer. In his new role, Evangelista will lead the company’s strategy, fundraising, and stakeholder management.
Evangelista expressed confidence in the newly formed team, stating, “Cairn has completed the required IND enabling tox studies to complete our IND. These were supportive of an already impressive set of data from both in vitro analysis and in vivo animal studies, and we are preparing for a Phase I trial next year to assess the safety in humans. We’ve assembled an outstanding management team that I am confident will enable us to meet our aggressive development milestones.”
Thomas Fritz joins the team as Chief Operating Officer, bringing with him invaluable experience from leading Cairn’s drug development efforts. Sutton T. Faller and Roger A. Rajewski, Ph.D., have also joined the management team as Chief Administrative Officer and Scientific Advisor, respectively.
In addition to the management team, Cairn has elected a new Board of Directors. The board includes W. Scott Evangelista, Roger Newton, Ph.D., and Wes Wheeler.
Roger Newton, co-discoverer of Lipitor® and founder of several pharmaceutical companies including Esperion Therapeutics, will serve as Chairman. Newton’s entrepreneurial success and vast experience in the pharmaceutical industry will provide valuable guidance to Cairn.
Wes Wheeler, recently retired President of UPS’s $10B Healthcare division, also joins the Board. Wheeler’s extensive leadership experience in multiple pharmaceutical companies, coupled with his crucial role in Operation Warp Speed during the Covid pandemic, will be instrumental in Cairn’s future direction.
The new leadership team and board members bring a wealth of industry experience and expertise to Cairn Therapeutics, positioning the company for its next phase of growth as it prepares for its Phase I trial next year.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.